An experimental heart drug by Swiss company Novatis has received several applauds by the global researchers and health experts for showing remarkable results in effectively treating the patients of cardiovascular diseases and heart woes.
According to the findings of a clinical trial, funded by the drug maker Novartis, the experimental medicines showed striking efficacy in treating the heart patients by lowering the death and hospitalization risk from the cardiovascular ailment by about 20 percent.
Health experts and doctors said that the Novartis drug, which doesn’t have a name yet and is known by its codename LCZ696, is a major breakthrough in the field of medical science. This rare drug is among those effective therapies that could quickly change the face of heart treatment by benefitting more than half of the six million people affected with the heart ailment in the United States and 24 million people worldwide.
“This is a new day for patients. It’s been at least a decade since we have had a breakthrough of this magnitude,” said Dr Clyde Yancy, cardiology chief at Northwestern University in Chicago.
Yancy, a former American Heart Association president, was not involved with the study.
Dr. Milton Packer, lead study author, lauded the impressive results, saying, “I think that when physicians see these data, they will find it compelling and what we will see is a paradigm shift.”
Dr. Packer is a clinical sciences professor at the University of Texas Southwestern Medical Center in Dallas.
Novartis carried a 27-month-old study and involved nearly 8,500 people from across 47 countries suffering from health woes. This was the largest experiment ever done in the field of heart medication.
The study investigators found that the Novartis drug reduced the death risk from heart-related problems by 20 percent in contrast to the 16 percent success rate of the older drug. The rate of hospitalization due to the heart failure also got lowered by an impressive 21 percent.
“We are really excited,” Packer said while adding, “The benefit exceeded our original expectations.”
The results of the clinical trial were presented before the European Society of Cardiology congress in Barcelona, Spain on Saturday. And the clinical research work and its findings were published online in the New England Journal of Medicine.
The drug maker will file for seeking the drug approval in the US in the end of this year. Novartis will seek Europe’s green signal for the drug in the first quarter of 2015. Hence, the experts say the effective drug would be available in the market by the end of this year.
Being a proprietary drug, Novartis is expected to offer the heart medicine at heavy price.